Entrectinib in NTRK fusion-positive non-small cell lung cancer
2 Views
administrator
07/07/23
Dr Luis Paz-Ares speaks to ecancer at the European Lung Cancer Congress 2019 about an integrated analysis of the STARTRK-2, STARTRK-1 and ALKA-372-001 trials.
Dr Paz-Ares outlines the mechanism of entrectinib in a genetically specific set of patients, and also the benefits specifically to those with CNS metastases.
He finalises by explaining the toxicity profile, but also that this drug should be given to more patients over a wider range of cancer types to provide more data.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
-
Category
Show more
Facebook Comments
No comments found